BECOME A LIFETIME MEMBER

Get additional small- and mid-cap investment opportunities and enjoy other privileges

Please fill out the form below

Price: USD 999 (lifetime subscription)

As a Lifetime Member you'll have access to:

  • 10 extensive research reports (PDF format) each year
  • Archive with all past research reports
  • Updates on previous research reports
  • Email alerts for reports and updates
  • 4 additional investment opportunities each year, sourced from small- and mid-caps (i.e., less liquid markets)*
  • Priority booking of reader events and trips*

* Exclusive for Lifetime Members only.

Upgrading your existing Annual Membership: If you are already an Annual Member, the unused part of the current year’s fees will be deducted from the total payable amount.

Do you want to pay by crypto, cheque, cash or bank transfer? Would you like to purchase a gift voucher? Please send me a message.

Tax-deductible invoices can be downloaded from your account after sign-up.

 

Most recent

More Weekly Dispatches

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.

All reports